

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Modern Chinese Medicine Group Co., Ltd.**

**現代中藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1643)**

### **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Modern Chinese Medicine Group Co., Ltd. (the “**Company**”) dated 19 January 2026 in relation to the major transaction regarding the acquisition of sale shares (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

As set out in the Announcement, it was expected that the Company would despatch a circular (the “**Circular**”) containing, among other matters, further information regarding the SPA and the transaction contemplated thereunder to the Shareholders for information purposes only in accordance with Rule 14.41(a) of the Listing Rules on or before 9 February 2026.

As additional time is required in finalising certain information for inclusion in the Circular, including the consolidated audited report of the Target Group for the three years ended 31 December 2025, the Company has applied for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the “**Waiver**”). It is expected that the despatch of the Circular will be delayed to a date on or before 30 April 2026.

The Company has applied to the Stock Exchange for the Waiver. As at the date of this announcement, the Waiver has not been granted by the Stock Exchange, further announcement will be made by the Company as and when appropriate.

By Order of the Board  
**Modern Chinese Medicine Group Co., Ltd.**  
**Zhang Hongli**  
*Executive Director*

Hong Kong, 9 February 2026

*As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.*